

Cell recognition and the immune system 2

Level: AQA AS 7401

Subject: Biology

Exam Board: Suitable for all boards

Topic: Cell recognition and the immune

system 2

Type: Mark Scheme

To be used by all students preparing for AQA AS Biology 7401 foundation or higher tier but also suitable for students of other boards.



Mark schemes

1	(a)		envelope/membrane/phospholipid (bilayer); capsid / nucleocapsid / capsomere / protein;	2	
		(i)	(HIV is) invading cells which make new viruses; Cells release viruses into blood;	2	
		(ii)	Virus remains dormant/exists as provirus/exists as DNA in host DNA; Accept virus stays in cells	1	
	(c)	Mor	destroys T cells; e (free) viruses produced leads to fall in T-cells; fewer) T-cells activate B-cells/memory cells;		
		Imm	luced/no antibody production; nune system not working properly/inability to fight infection; portunistic infections;		
			4 m	ıax	[9]
2	(a)	Nuc	eleus;	1	
	(b)	Ena	bles organism to remain in area (of food source) / prevent its removal; • Q To attach' is not sufficient unless qualified	1	
	(c)	(i)	Correct answer of 222(%);;		
			Incorrect answer that clearly identifies difference in number of cases as 5800 –1800 or 5.8 – 1.8; Correct answer gains two marks		
		(ii)	More water-related activities / more 'organisms' with increased temperature; • • Allow any reference to growth or replication of 'organisms'. Do not penalise reference to bacteria.	2	
			Q Do not allow increase in water consumption.	1	
	(d)	(i)	All have same shape / only binds to Giardia / one type of / specific antigen;	1	



		(ii)	Has complementary (shape) / due to (specific) tertiary structure / variable region (of antibody); • Q Binds / fits not sufficient unless qualified;	1	
		(iii)	Enzyme / second antibody would remain / is removed by washing;		
			Enzyme can react with substrate (when no antigen is present);	2	[9]
3	(a)	Pha	gocytes engulf / ingest pathogens / microorganisms / bacteria / viruses;		
		Phag	gocytes destroy pathogens / microorganisms / bacteria / viruses;		
		Lung	g diseases are caused by pathogens / microorganisms / bacteria / viruses; • Q Allow description of process of engulfing	2 max	
	(b)	(i)	Alveoli / lungs will not inflate / deflate fully / reduced lung capacity;		
			Breathing out particularly affected / no longer passive;	2	
		(ii)	Alveolar walls thicken;		
			Longer diffusion pathway;		
			Scarred / fibrous tissue;		
			Reduces <u>surface area</u> (for gaseous exchange); Q Diffusion is essential for 2 nd point and surface area for 4 th point.	4	
	(c)	(i)	Cancer develops 20 – 30 years after exposure (to asbestos);	1	
		(ii)	Smoking / air pollution / specified industrial source;	1	[10]
1	(a)	Pha	gocytes engulf pathogens / microorganisms;		
		Encl	osed in a vacuole / vesicle / phagosome;		
		Lyso	somes have enzymes;		
		That	digest / hydrolyse molecules / proteins / lipids / microorganism;	3 max	



	(b)	(i)	Get another strain / there are different strains;		
			Therefore does not have memory cells against second strain; • Q The second marking point should only be awarded in the context of memory cells.	2	
		(ii)	Vaccines only work against certain strains because the antigens they possess are different;		
			Enables company to target strain likely to be prevalent later / most common strain;	2	
				2	[7]
5	(a)	(i)	Many people do not go to the doctor;	1	
		(ii)	36000;		
			No marks awarded for working here as calculation is very straightforward	1	
	/ b \	Com	an augura / antigana an hagtaria / nam/a aglla.	1	
	(b)	San	ne sugars / antigens on bacteria / nerve cells; Do not accept references to same shape as equivalent to complementary.		
		Bind	d with antibody / form antigen-antibody complex; Reject react		
		Hav	e complementary shape / fit binding site; Reject active site		
				3	
	(c)	Diap	ohragm will not move down / flatten / contract; Ignore references to breathing out		
		Tho	racic cavity / lung volume not increased so cannot breathe in;	2	[7]
6	(a)		ecule / part of molecule / protein / glycoprotein / named molecule; stimulates an immune response / eq;	2	
	(b)		de by mitosis / form clones; produce plasma cells; (plasma cells)	2	
			se antibodies; sma cells) produce memory cells;	4	
				-	



(c)	(i)	glycoprotein AND different shape to body proteins / RNA and reverse transcriptase inside virus / phospholipids same as body's / on the surface of the virus;	1	
	(ii)	187.5;; Accept 187 – 188 1 mark for HIV = 80nm;	2 max	ro
(a)	prod (plas	le by mitosis / form clones; luce plasma cells; sma cells) make antibodies; sma cells) produce memory cells;	4	[9]
(b)	diffe loca	oprotein; rent shape to body proteins / body phospholipids are the same / ted on the outside of the cell / the haemoglobin is located le the cell;	2	[6]
(a)	(Ant	ction of antigens / toxoids; igen from) attenuated microorganism / non-virulent oorganisms / dead		
	micr	oorganisms / isolated from microorganism;		
	Stim	ulates the formation of memory cells;	max 2	
(b)	(i)	Antibodies are specific to mumps antigen; 2nd antibodies specific to mumps antibody;	1	
	(ii)	Removes unbound 2 nd antibodies; Otherwise enzyme may be present / may get colour change anyway / false positive;	2	
	(iii)	No antibodies to bind (to antigen); Therefore 2 nd antibody (with the enzyme) won't bind / no enzyme / enzyme-carrying antibody present (after washing in step 4);	-	
		(altor washing in step +/,	2	

8

[7]



9	(a)	Stimulates memory cells;		
		Secondary response, so antivenom / antibodies produced quicker;	2	
	(b)	Passive immunity; so no memory cells produced;		
		Antivenom breaks down / destroyed;	2	
	(c)	Could transfer disease / Allergy / Immune response to antibodies from animal;		
		nom animal,	1	[5]
10	(a)	add antibodies / enzyme; wash to remove unbound antibodies; add (colourless) solution;		
		(mark correct responses sequentially)	3	
	(b)	antibodies specific / shape only fits one antigen; other antigens different shape and would not bind to antibodies;	2	
11	(a)	(i) protein / immunoglobulin; specific to antigen; idea of 'fit' / complementary shape;	2 max	[5]
		 (ii) 1. virus contains antigen; 2. virus engulfed by phagocyte / macrophage; 3. presents antigen to B-cell; 4. memory cells / B-cell becomes activated; 5. (divides to) form clones; 6. by mitosis; 7. plasma cells produce antibodies; 8. antibodies specific to antigen; 9. correct reference to T-cells / cytokines; 	6 max	
	(b)	 antibody gene located using gene probe; cut using restriction enzyme; at specific base pairs; leaving sticky ends / unpaired bases; cut maize / DNA / vector using same restriction enzyme; join using DNA ligase; introduce vector into maize / crop / recombinant DNA into maize; 	4 max	



	(c)	passive / person is not making own antibodies / antibodies not replaced; memory cells not produced;	2	
	(d)	fewer ethical difficulties / less risk of infection;	1	[15]
12	(a)	To prevent contamination of apparatus with other microorganisms / bacteria; To prevent personal contact with bacteria; To prevent release of bacteria into air;		
	(b)	(i) Diffuses slowly;	max 2	
		(ii) B; Produces inhibition zone greater than the minimum diameter;	2	[5]
13	(a)	Publicity about vaccination / better health education / risks of 'flu epidemics; (Accept: now free on NHS (though only since 2000) / better awareness / more commonly available)	1	
	(b)	 (i) 1990: 26% of 7.4million = 1.92million and 2000: 64% of 7.8 million = 4.99million; increase = 3.07 million; (Correct reading of all 4 figures from graph = 1) (Correct answer but no 'millions' = 1) (Correct method resulting from wrong graph reading = 1) 	2	
		(ii) Over 50% of population being vaccinated; But only from 2000 onwards; (Principle of more people being vaccinated each year = 1)	2	
		(iii) Different strain / type of virus each year / virus mutates; With different antigens; Influenza antibodies / memory cells (rapidly) destroyed / need replacing;	max 2	
	(c)	(Protein coat) carries antigens which stimulates B-cells / production of antibodies; Production of memory cells;	2	[9]

14	(a)	(i)	protein / glycoprotein / glycolipid / polysaccharide / molecule; on surface / membrane (of cell); causes immune response / description / triggers antibody production;		
			p	max 2	
		(ii)	reference to hybrid cell from tumour / cancer and B-lymphocyte / hybridoma; antibodies all the same / from one type of plasma cell; specific to / complementary to / fits only one antigen;		
				max 2	
	(b)	(i)	antibodies specific / only binds to PSA; PSA only associated with prostate cancer / not with other diseases;	2	
		/::\	and the advanced by a second and a second and a second and	2	
		(ii)	antibody with enzyme only attaches if PSA present / washed away if no PSA;		
			no colour change without enzyme;		
				2	[8]
	(2)	molo	ecule (on cell surface);		
15	(a)		triggers immune response;		
				2	
	(b)	(i)	axes right way round and labelled;		
			2nd peak drawn higher; steeper gradient on second rise;		
			g. a.ae eeeeaee,	3	
		(ii)	because one dose does not give a high enough level of		
			antibody to be effective / because the antibody falls after a while;		
				1	
		(iii)	antigens are only single molecules / part of parasite; do not actually cause disease;		
			do not dotadny oddoo dioodoo,	2	
	(c)	mala	uria sufferers would have parasites in red blood cells;		
				1	
					[9]
16	(a)	Resi	sence of resistant and non-resistant varieties / mutation produces resistant variety; stant ones survive / non-resistant ones killed by treatment;		
		Thes	se will reproduce and produce more resistant parasites / pass on resistance allele;	;	
	(b)		lihood of being infected (by strain resistant to both drugs) is less; 0 × 1/500/1/250 000;		
			has longer effective life;		
				max 2	



(c)	(i)	As comparison / to show that nothing else in the treatment was responsible;	1	
	(ii)	Given injections of saline / injection without SPf66;		
	(,	(otherwise) treated the same as experimental group;		
		(concentration and control and control and group)	2	
(d)	(i)	100%;		
			1	
	(ii)	10%;		
	()	,	1	
	•			
(e)	(i)	Different lengths of DNA have different base sequences / cut at specific		
		sequence;		
		Results in different shape / different shape of active site;		
		Therefore (specific sequence) will only fit active site of enzyme;	3	
			3	
	(ii)	Recognition sites contain only AT pairs;		
		Which would occur very frequently;		
			2	
				[15]
(2)	cido	effects / allergic reactions / low toxicity to cells;		
(a)		action with other drugs / effective in conditions of use / reasonably stable;		
		action with other drugs? effective in conditions of use? reasonably stable, ald only act on the problem bacteria / narrow spectrum;		
		much resistance the bacteria have built up;		
			2 max	
(b)	(i)	tetracycline		
		prevents tRNA binding to ribosomes / amino acid / mRNA;		
			1	
		amino acids not available / brought / picked up;		
		3 1 17	1	
		chloramphenicol		
		prevents <u>amino acids</u> being joined / prevents primary structure forming;	1	
			1	
		no enzymes / no structural proteins formed;		
		(accept cell wall formation if qualified) (prevents protein synthesis		
		gains one mark in either section, once only)		
		3	1	
	4115			
	(ii)	only prevents tRNA binding to 70S / prokaryotic / bacterial		
		ribosomes / human ribosomes are different sizes / shapes / structure;		
			1	r
				[7]

17

	 macrophages present antigens to B lymphocytes; antigen binds to / is complementary to receptors on lymphocyte; binds to a specific lymphocyte; lymphocytes become competent / sensitised; (B) lymphocytes reproduce by mitosis / (B) lymphocytes cloned; plasma cells secrete antibodies; 	(a)	18
· [7]	 restriction enzyme / endonuclease; to cut plasmid / to form sticky ends in plasmid; (use) ligase(to join) gene to plasmid; culture bacteria with (in medium containing) plasmids to allow uptake of plasmids / transformation; use of cold shock / chemical treatment (to enhance uptake) / heat shock; (ignore bullets / electroporation / microinjection) 	(b)	
L ^r .	bacteria have ligands / antigens / proteins / glycoproteins / polysaccharides (on membrane / wall);	(a)	19
	complementary to receptors / fits / binds / attaches to specific receptor		
	enzymes denatured / tertiary / secondary structure altered / altered active sites / breaks hydrogen bonds;	(b)	
	prevents named chemical reactions / metabolic pathways; 1		
	inhibits / kills other bacteria / fungi / decomposers / reduces competition;	(c)	
	 (accept mix bacteria with agar / medium) with oil and one with control / water / range of concentrations; appropriate method of standardising how sample applied, e.g. discs / wells; appropriate measure of effectiveness / size / diameter of clear zone; the larger the zone the greater the effectiveness; use of aseptic technique; 	(d)	
[9]	(ignore haemocytometer) 4 max		
	1360 = 2 marks (general principle 0.68 ÷ 0.05 x 100 gains 1 mark)	(i)	20
	still have maternal antibodies;	(ii)	
	-		

[3]

21	(a)	(i)	fall in deaths due to rise in number of people with immunity / better care / ta vaccination at vulnerable;	rgeting	
				1	
		(ii)	mutation of virus / new strain;		
			mutant form not recognised by memory cells (allow antibodies);	2 max	
	(b)	(i)	T lymphocyte receptors recognise shape of haemagglutinin / neuraminidase / viral antigen; clone (<i>once only</i>); destroy virus;		
				2 max	
		(ii)	clone (<i>once only</i>); produce antibodies;		
			effect of antibody e.g. stimulation of phagocytosis /		
			precipitation of toxins;	2	
	(c)		s unable to leave host cells;		
				2	[9]
22	(a)		nory B / T cells do not recognise (new antigens);		
			oodies previously produced are not effective hape not complementary to new antigen;		
		as s	mape not complementary to new antigen,	2	
	(b)	(i)	antigen in membrane presented to lymphocytes / produce cytokinins;		
				1	
		(ii)	mitochondria provide (more) ATP / energy;		
			<pre>(more) RER / ribosomes synthesise proteins; (more) Golgi body secretes / modifies or packages proteins / produces glycoproteins;</pre>		
			(B lymphocytes) produces antibodies;		
				4	[7]
23	(a)	47 2	213;	1	
	41.	(1)		1	
	(b)	(i)	there is no difference in the proportion / number of influenza cases between the 5 vaccines;		
			(reject vaccinated versus no vaccinated)	1	
		(ii)	significant difference in proportion / number of cases of influenza between the vaccines / the null hypothesis should be rejected;		
			Temperature rademice, and main repositions official be rejected,	1	



sample size small;
 possible differences in exposure to infection;
 exposure to different strains / mutants;
 possible differences in existing immunity;
 possible differences in sex / age;
 possible differences in socio-economic status;

2 max

[5]

24

(a) Microorganism alive/active;
 But does not cause symptoms of disease/Avirulent;
 Accept does not make you ill/harm

2

(b) (i) (Takes time for) antigen to be recognised;

Accept reference to presentation by macrophage for first marking point

(Takes time for) T cells to be activated;

Accept primary (immune) response

B-cell activation/clonal selection/expansion; Plasma cells to make (specific) antibodies; Time for enough antibodies to measure;

2 max

(ii) Memory cells (present);

Accept secondary (immune) response

Respond immediately / can produce antibodies immediately;

2

[6]

25

(a) Reverse transcriptase;

Accept integrase/description of action of

Enzyme uses (HIV) RNA to make DNA (copy);

DNA joined to (host) cell's DNA/chromosome;

DNA used to make HIV RNA (copies);

Accept (HIV) DNA replicated when (T) cell divides

And HIV capsid proteins/enzymes;

Made at (host) ribosomes;

Assembly of new virus particles;

Budding off from membrane (of host cell);



(b) Not enough/no T-cells to activate B-cells/lead to antibody production/ activate immune system;

Accept death of T-cells weakens the immune system

Person unable to fight /more prone to (opportunistic) infections/cancer; Accept diseases

Example of infection/cancer;

E.g. TB, pneumonia, cryptosporidium

2 max

[6]

26

(a) Zevalin/antibody binds to specific receptor/cell surface protein/antigen;

(Only found) on B-cells;

2

(b) Patient **P** treated with Zevalin/yttrium (no mark);

Assume 'Zevalin' means 'with yttrium' unless they state otherwise

Where indium/antibody (only) on lymphatic system/groin and armpits;

So only (cancerous) B-cells killed;

In patient **P** high concentration of radioactivity/antibodies high enough to kill cancer cells;

Patient **Q** – radioactivity in places where other body cells could be killed/ organs damaged/named example;

Could harm patient more than cancer;

Patient **Q** cancer has spread;

So too late to treat;

3 max

(c) Patient **Q** – (cancerous) B-cells outside of lymphatic system/metastasis;

So antibody bound in other parts of the body (as well);

Patient **Q** – has different receptors/distribution of receptors compared to patient **P**;

Other body cells (than B-cells) have receptors for antibody;



(d) Might be allergic to mouse antibody/protein;

(Mouse) antibody acts as an antigen;

Causes an immune response/antibody production;

Antibody destroys Zevalin;

Releases radioactivity into body/prevents activity against the cancer;

2 max

[9]

27

(a) Correct answer: 1.25;

Ignore working

OR (if wrong answer)

$$\frac{\text{measurement in } \mu\text{m}}{40000} / \frac{\text{measurement in mm}}{40} = 1 \text{ mark}$$

125 but wrong order of magnitude = 1 mark

2

(ii) **C** has myosin / thick (and actin / thin) filaments;

OR

A has only actin / thin (/ no myosin / no thick) filaments;

1 max

(b) When contracted:

Thick & thin filaments/myosin & actin overlap more;

Interaction between myosin heads & actin / cross-links form;

Movement of myosin head;

Thin filaments / actin moved along thick filaments / myosin;

Movement of thin filaments / actin pulls Z-lines closer together;

Displacement of tropomyosin to allow interaction;

Role of Ca²⁺;

Role of ATP:

Allow ref. to 'sliding filament mechanism' / described if no other marks awarded



(c)	(i)	8 has DMD but 3 and 4 do not / 12 has DMD but 6 and 7 do not / neither parent has the condition but their child has; Allow parents 3 and 4 give 8, parents 6 and 7 give 12	
	(ii)	4 AND 7;	1
	(iii)	Parental genotypes: $6 = \mathbf{X}^{D}\mathbf{Y}$ AND $7 = \mathbf{X}^{D}\mathbf{X}^{d}$	
		AND	
		Gametes correct for candidate's P genotypes – e.g.	
		\mathbf{X}^{D} and $\mathbf{Y} + \mathbf{X}^{D}$ and \mathbf{X}^{d} ;	
		Offspring genotypes correctly derived from gametes e.g.	
		$X^{D}X^{D} + X^{D}X^{d} + X^{D}Y + X^{d}Y;$	
		Male offspring with MD correctly identified: XdY;	
		Probability = 0.25 / correct for candidates offsprings genotypes; Accept ½ / 1 in 4 / 1:3 / 25% NOT '3:1' / '1:4'	
		NOT 0.17 1.4	4
(d)	(i)	No gene fragment G ;	1
	(ii)	Only one copy of gene fragment F ;	
		Male has only one X-chromosome / is XY	
		(c.f. female has two / is XX);	2
	(iii)	10 has only one copy of gene fragment G ;	
		10 has only one normal X-chromosome / has one abnormal / has only one normal allele / has one X ^d / is X ^D X ^d / is heterozygous;	
		11 has two normal X-chromosomes / has 2 normal alleles / is $X^D X^D$ / has not got X^d / has 2 copies of (F and) G;	1
(e)	(i)	To prevent rejection / prevent antibody production vs. injected cells / injected cells have (foreign) antigen (on surface);	1
	(ii)	Shows effect of cells / not just effect of injection / not just effect of salt solution:	-



(iii) Only one person tested so far – need more to see if similar results / need more to see if reliable:

Need to assess if new (dystrophin positive) muscle fibres are functional / if muscle becomes functional;

Can't tell how widespread effect is in the muscle / sample taken near injection site;

Need to test for harmful side effects;

Need to test if successful for other mutations of dystrophin gene;

Need to assess permanence / longevity of result/insufficient time allowed in investigation;

(In this patient) only small response / %;

Further sensible suggestion;

4 max

[25]

(a) (i) P = membrane / lipid envelope / phospholipid bilayer;

Q = reverse transcriptase;

Accept (host) cell membrane;

2

(ii) Carries genetic information / to make DNA;

Q Do not accept 'information' on its own Accept genes, alleles, to make (viral) protein;

1

(b) DNA copy made (of viral RNA);

Inserted into host DNA / chromosomes;

(Uses viral DNA to) make viral proteins/particles;

Makes viral RNA;

28

29

(Host) cell makes new viruses;

"Budding off" / wrapped in cell membrane;

Accept reverse transcriptase makes DNA for 2 marks in correct context:

3 max

[6]

(a) (i) Molecule/protein/glycoprotein;

Stimulates immune response;

(That causes) production of antibodies;

2 max

(ii) Antigens on HIV are different (shape);

So, antibody will not 'fit'/not complementary (to antigen);

Receptor sites on antibody specific to one antigen;



(iii) (Has site with) same shape as salmonella antigen so binds to anti-gal antibodies;
 (Has site with) same shape as receptor molecule so that HIV will bind;
 Binds to both molecules;

2 max

(b) Salmonella pathogen has specific antigen on surface;

Salmonella pathogen engulfed by macrophage;

T-cells activate B-cells;

B-cell with complementary/specific receptor antibody activated/ clonal selection;

B-cells divide/form clone/clonal expansion;

Plasma cells make antibodies;

Specific to antigen/bind to salmonella bacterial antigen;

Accept macrophage presents antigen to T/B cells;

Accept T-cells release factors;

6 max

(c) (i) HIV binds to specific receptor;
Only present on certain cells / T-cells;

2

(ii) Antibiotics stop metabolism, viruses don't have metabolism; Viruses hide in cells, antibiotics can't reach;

Two suitable cell components antibiotics work against that viruses don't have:

e.g. some antibiotics work against ribosomes, that viruses don't have

2

(d) (i) Adaptor molecule binds to HIV;

(This) prevents the HIV binding to the receptor;

Therefore few HIV available to infect cells;

2 max

(ii) Would need to be complementary to MRSA (antigens);

MRSA has different antigens;

But would still need to have binding site for anti-gal;

2 max

[20]

(a) Protein / molecule/glycoprotein;

30

On surface of cell/microorganism;

Stimulates immune response/production of antibodies;



(b) Zookeeper is not producing antibodies/passive immunity; No memory cells made;

OR

Antivenom is an antigen/stimulates production of (anti-antivenom) antibodies; (Antivenom) destroyed by zookeeper's own antibodies;

OR

Antibody destroys antigen/venom;

Before immune response/no immune response;

[4]

2

31

(a) Cotinine is an antigen;

Antigen/cotinine binds to (specific) T-cell/activates T-cell;

T-cell activates B-cells;

Specific B cell becomes activated;

(Specific) B cell divides/ clonal expansion;

Forms (clone of) plasma cells;

(Plasma) cell produces antibodies;

Accept macrophage presents antigen for one mark Ignore references to memory cells and secondary immune response

4 max

(b) Antibodies are proteins with tertiary structure/specific shape/binding sites;
 Antibodies specific shape for cotinine;
 Only cotinine fits;

Do not credit active site

2

[6]



32	(a)

(a) Damage / destruction of cells / tissues;Production of toxins;

2

(b) Contains antigen / proteins / dead / weakened microorganism / pathogen / virus / bacteria;

Stimulates production of antibodies / plasma cells / memory cells;

Q Do not credit immune response unless qualified.

2

(c) (i) Age;

Sex;

Ethnicity;

All healthy / not on other medication;

Not previously vaccinated / infected with TB;

Q Do not credit sample size.

Q Allow any suitable reference to health not being affected for fourth marking point e.g. smoking, 'depressed immune system' etc.

2 max

(ii) Contain the same antigens;

1

[7]